DALLAS, May 6, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Osiris Therapeutics Inc. (Nasdaq:OSIR). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/OSIR
Osiris Therapeutics Inc. (OSIR) is a stem cell therapeutic company. It focuses on developing and marketing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. The Company's biologic drug candidate, Prochymal, is being evaluated in phase III clinical trials for four indications, including acute and steroid refractory graft versus host disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure. Its pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee. The Company is partnered with Genzyme Corp. to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies.
Message Board Search for OSIR: http://www.boardcentral.com/boards/OSIR
In the report, the analyst notes:
"Net income for the fourth quarter of 2009 was $15.7 million compared to a net loss of $7.8 million in the fourth quarter of 2008. Revenues were $10.8 million in the fourth quarter of 2009, consisting primarily of upfront license fees from the Genzyme agreement and our research, development and commercialization agreement with JDRF. Revenues during the fourth quarter of 2008 were $6.2 million.
"OSIR this week announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States."
To read the entire report visit: www.microstockprofit.com/ads/OSIR
See what investors are saying about OSIR at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.